Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer.
Rojas L K, Trilla-Fuertes L, Gámez-Pozo A, Chiva C, Sepúlveda J, Manso L, Prado-Vázquez G, Zapater-Moros A, López-Vacas R, Ferrer-Gómez M, Mendiola C, Espinosa E, Sabidó E, Ciruelos E, Vara JÁF. Rojas L K, et al. Among authors: sepulveda j. Ecancermedicalscience. 2019 Jan 15;13:891. doi: 10.3332/ecancer.2019.891. eCollection 2019. Ecancermedicalscience. 2019. PMID: 30792808 Free PMC article.
Urothelial cancer proteomics provides both prognostic and functional information.
de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sepúlveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D. de Velasco G, et al. Sci Rep. 2017 Nov 17;7(1):15819. doi: 10.1038/s41598-017-15920-6. Sci Rep. 2017. PMID: 29150671 Free PMC article.
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E, Apellániz-Ruiz M, Cantos B, Martinez-Jáñez N, Bueno-Muiño C, Echarri MJ, Enrech S, Guerra JA, Manso L, Pascual T, Dominguez C, Gonzalo JF, Sanz JL, Rodriguez-Antona C, Sepúlveda JM. Ciruelos E, et al. Oncologist. 2019 Nov;24(11):e1024-e1033. doi: 10.1634/theoncologist.2017-0664. Epub 2019 Apr 25. Oncologist. 2019. PMID: 31023863 Free PMC article. Clinical Trial.
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G. Carretero-González A, et al. Among authors: sepulveda jm. Oncotarget. 2018 Jan 20;9(9):8706-8715. doi: 10.18632/oncotarget.24283. eCollection 2018 Feb 2. Oncotarget. 2018. PMID: 29492229 Free PMC article.
HDM2 overexpression and focal loss of p14/ARF expression may deregulate the p53 tumour suppressor pathway in meningeal haemangiopericytomas. Study by double immunofluorescence and laser scanning confocal microscopy.
Martínez JC, Palomino JC, Cabello A, Sepúlveda JM, de la Cámara AG, Ricoy JR. Martínez JC, et al. Among authors: sepulveda jm. Histopathology. 2005 Feb;46(2):184-94. doi: 10.1111/j.1365-2559.2005.02074.x. Histopathology. 2005. PMID: 15693891
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Castellano D, González-Larriba JL, Antón-Aparicio LM, Cassinello J, Grande E, Esteban E, Sepúlveda J. Castellano D, et al. Among authors: sepulveda j. Expert Opin Pharmacother. 2011 Nov;12(16):2433-9. doi: 10.1517/14656566.2011.590132. Epub 2011 Jun 15. Expert Opin Pharmacother. 2011. PMID: 21671835 Clinical Trial.
423 results